Based on the subgroup analysis of the ADAURA trial data, adjuvant osimertinib significantly enhanced DFS (HR 0.41) for patients diagnosed with EGFR-mutated stage IB NSCLC compared to placebo (46). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.